Celcuity's Cancer Drug Expansion Could Ignite Massive New Market Opportunity: Analyst
Celcuity Inc. (CELC) Q1 2026 Earnings Call Transcript
Celcuity Q1 Earnings Call Highlights
Celcuity Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update
Celcuity's Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients
Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call
Why Is Celcuity Stock Rallying Today?
Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort
Celcuity: Best-In-Class Potential With 2-3x Upside If Mutant Data Delivers
Why Celcuity Stock Popped on Monday
Nisa Investment Advisors LLC Decreases Stock Holdings in Celcuity, Inc. $CELC
Why Celcuity Stock Popped Today
Celcuity Inc. (CELC) Q4 2025 Earnings Call Transcript
Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call
Celcuity, Inc. (NASDAQ:CELC) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug
Celcuity Inc. (CELC) Presents at Leerink Global Healthcare Conference 2026 Transcript
Apis Capital Trims Holdings of Celcuity Stock, According to Recent SEC Filing
Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology
Celcuity Inc. (CELC) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Choreo LLC Takes Position in Celcuity, Inc. $CELC
Celcuity CEO Details Gedatolisib NDA, July PDUFA and Launch Plans at TD Cowen Conference
Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing
Artisan International Small-Mid Fund Q4 2025 Performance Review
Celcuity To Participate in Upcoming Investor Conferences
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position
Celcuity, Inc. (NASDAQ:CELC) Given Average Rating of “Moderate Buy” by Brokerages
Celcuity Inc. (CELC) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
Has Celcuity (CELC) Outpaced Other Medical Stocks This Year?
Soleus Adds a Significant Number of Celcuity Shares
Celcuity Appoints Charles Romp to its Board of Directors
AlTi Global Inc. Purchases New Shares in Celcuity, Inc. $CELC
Celcuity, Inc. $CELC Stake Boosted by New York State Common Retirement Fund
Director Sells 20,000 Celcuity Shares for $2.4 Million Following 933% Share Price Jump
Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026
Celcuity, Inc. (NASDAQ:CELC) Short Interest Up 20.9% in December
Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer
Celcuity Stock Up 677% in 6 Months: What's Behind This Huge Increase?
Celcuity, Inc. (NASDAQ:CELC) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Celcuity: After Stellar 2025, I Predict More Success In 2026 And Beyond
5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026
Tracking the Top-Performing Russell 2000 Stocks Against the Zacks Rank
Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium
3 Stocks You'll Wish You Bought Before 2026
Celcuity Stock Near All-Time Highs — And This Major Biotech Investor Is Still Jumping In
This Fund Bought $38 Million of Celcuity as Stock Surges on Investigational Cancer Drug Results
Celcuity: From Speculative Bet To Pre-Commercial Powerhouse
This Fund Bought $38 Million of Celcuity as Stock Surges on Investigational Cancer Drug Results
Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium